Bamosiran

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameBamosiran
Drug Alias Namebamosiran巴莫西兰syl040012巴莫赛兰bamosiranum +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionBeta-2 adrenergic receptor antagonistsRNA interference
TargetsBeta-2 adrenergic receptor
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanySpain +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharma Mar SaSylentis Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSylentis Sa
Active IndicationsN/A
Inactive IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A